Schroder, Carmen M.
Malow, Beth A.
Maras, Athanasios
Melmed, Raun D.
Findling, Robert L.
Breddy, John
Nir, Tali
Shahmoon, Shiri
Zisapel, Nava
Gringras, Paul
Funding for this research was provided by:
Neurim Pharmaceuticals Ltd
Article History
First Online: 11 May 2019
Compliance with Ethical Standards
:
: AM, BAM and CMS were investigators, PG was the chief investigator and paid consultants, RLF was the chief investigator and receives or has received research support, acted as a consultant and/or served on a speaker’s bureau for Aevi, Akili, Alcobra, Amerex, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Bracket, Epharma Solutions, Forest, Genentech, Guilford Press, Ironshore, Johns Hopkins University Press, KemPharm, Lundbeck, Merck, NIH, Neurim, Nuvelution, Otsuka, PCORI, Pfizer, Physicians Postgraduate Press, Purdue, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Syneurx, Teva, Tris, TouchPoint, Validus, and WebMD, JB was the study statistician of the study all were paid by Neurim Pharmaceuticals and declare no interests. SS and TN are employees and NZ is the founder and Chief Scientific Officer of Neurim Pharmaceuticals.
: The trial complied with the principles of the Declaration of Helsinki (1989) and standards of good clinical practices. All participants and parents/legal guardians provided written, signed informed assent and consent, respectively, prior to participation, under procedures and local regulations of each country. ClinicalTrials.gov Identifier: NCT01906866.